Cerebral ischaemia: Tomorrow's therapeutic tracks;Ischémie cérébrale: Les pistes thérapeutiques de demain

Medecine/Sciences

Volumn 25, Issue 10, 2009, Pages 847-854

  Bordet, Régis ^a   Ouk, Thavarak ^a   Onténiente, Brigitte ^b   Charriaut Marlangue, Christiane ^c   Heurteaux, Catherine ^d  

^a UNIV LILLE   (France)

^b Parc Scientifique de Luminy   (France)

^c CNRS   (France)

^d INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; APTIGANEL; CITICOLINE; CP 103606; DARODIPINE; DEXTRORPHAN; DIAZEPAM; DISUFENTON SODIUM; ELIPRODIL; FLUNARIZINE; FOSPHENYTOIN SODIUM; GAVESTINEL; GLYCINE; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1; NALMEFENE; NALOXONE; NIMODIPINE; PICLOZOTAN; PIRACETAM; REMACEMIDE; REPINOTAN; ROVELIZUMAB; SIPATRIGINE; SUNN 4057; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONAMPANEL; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID;

APOPTOSIS; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CELL THERAPY; CLINICAL TRIAL; DEPOLARIZATION; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; PLEIOTROPY; REHABILITATION CARE; REVIEW; RISK ASSESSMENT; STROKE;

EID: 70350330445     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20092510847     Document Type: Review

References (36)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008 ; 371 : 1612-1632
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 ; 359 : 1317-1329
3. J. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008 ; 55 : 363-389
4. Del Zoppo GJ. Inflammation and neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009 ; 158 : 972-982
5. Shpargel KB, Jalabi W, Jin Y, et al. Preconditioning paradigms and pathways in the brain. Cleve Clin J Med 2008 ; 75 : S77-82.
6. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother 2008 ; 8 : 1193-1201
7. Endres M, Engelhardt B, Koistinaho J, et al. Improving outcome after stroke : overcoming the translational roadblock. Cerebrovasc Dis 2008 ; 25 : 268-278
8. Obrenovitch TP. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 2008 ; 88 : 211-247
9. Stenzel-Poore MP, Stevens SL, King JS, Simon RP. Preconditioning reprograms to response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes : a speculative synthesis. Stroke 2007 ; 38 (suppl 2) : 680-685
10. Bastide M, Ouk T, Plaisier F, et al. Neurogliovascular unit after cerebral ischemia: is the vascular wall a pharmacological target. Psychoneuroendocrinology 2007 ; 32 : S36-9.
11. Goldstein LB. Statins and ischemic stroke severity: cytoprotection. Curr Atheroscler Rep 2009 ; 11 : 296-300.
12. Bordet R, Ouk T, Petrault O, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006 ; 34 : 1341-1346
13. Blondeau N, Widmann C, Lazdunski M, Heurtaux C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience 2002 ; 109 : 231-241
14. Deplanque D, Masse I, Lefebvre C, et al. Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology 2006 ; 67 : 1403-1410
15. Zaleska MM, Mercado ML, Chavez J, et al. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology 2009 ; 56 : 329-341
16. Bordet R, Lestage P, Onteniente B. The concept of neuroprotective agents as a treatment modulators in the development of brain diseases. Therapie 2007 ; 62 : 463-472
17. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009 ; 40 : 2244-2250
18. Feuerstein GZ, Zaleska MM, Krams M, et al. Missing steps in the STAIR case : a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab 2008 ; 28 : 217-219
19. Benchenane K, Castel H, Boulouard M, et al. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J Cell Sci 2007 ; 120 : 578-585
20. Heurtaux C, Laigle C, Blondeau N, et al. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 2006 ; 137 : 241-251
21. Haddad M, Rhinn H, Bloquel C, et al. Anti-inflammatory effects of PJ34, a poly (ADP-ribose) polymerase inhibitor, in transcient focal cerebral ischemial in mice. Br J Pharmacol 2006 ; 149 : 23-30.
22. Chauvier D, Ankri S, Charriaut-Marlangue C, et al. Broad-spectrum caspase inhibitors : from myth to reality ? Cell Death Differ 2007 ; 14 : 387-391
23. Onténiente B. Natural and synthetic inhibitors of caspases : targets for novel drugs. Curr Drug Targets CNS Neurol Disord 2004 ; 3 : 333-340
24. Guégan C, Braudeau J, Couriaud C, et al. PTD-XIAP protects against cerebral ischemia by anti-apoptotic and transcriptional regulatory mechanisms. Neurobiol Dis 2006 ; 22 : 177-186
25. Spahn A, Blondeau N, Heurteaux C, et al. Concomitant transitory up-regulation of X-linked inhibitor of apoptosis protein (XIAP) and the heterogeneous nuclear ribonucleoprotein C1-C2 in surviving cells during neuronal apoptosis. Neurochem Res 2008 ; 33 : 1859-1868.
26. Lok J, Gupta P, Guo S, et al. Cell-cell signalling in neurovascular unit. Neurochem Res 2007 ; 32 : 2032-2045
27. Villapol S, Gelot A, Renolleau S, Charriaut-Marlangue C. Astrocyte responses after neonatal ischemia : the yin and the yang. Neuroscientist 2008 ; 14 : 339-344
28. Amantea D, Nappi G, Bernardi G, et al. Post-ischemic brain damage : pathophysiology and role of inflammatory mediators. FEBS J 2009 ; 276 : 13-26.
29. Fisher M. Injuries to the vascular endothelium: vascular wall and endothelial dysfunction. Rev Neurol Dis 2008 ; 5 : S4-11.
30. Gautier S, Ouk T, Petrault O, et al. Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia. Br J Pharmacol 2009 ; 156 : 673-679
31. Zhao BQ, Tejima E, La EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007 ; 38 (suppl 2) : 748-752
32. Minnerup J, Schäbitz WR. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 2009 ; 6 : 43-52.
33. Rodriguez-Gonzalez R, Hurtado O, Sobrino T, Castillo J. Neuroplasticity and cellular therapy in cerebral infarction. Cerebrovasc Dis 2007 ; 24 : S167-80.
34. Tardy J, Pariente J, Leger A, et al. Methylphenidate modulates cerebral post-stroke reorganization. Neuroimage 2006 ; 33 : 913-922
35. Bacigaluppi M, Pluchino S, Martine G, et al. Neural stem/precursor cells for the treatment of ischemic stroke. J Neurol Sci 2008 ; 265 : 73-77
36. Vivien D, Gauberti M, Guedin P, Anglés-Cano E. Comment optimiser l'utilisation du tPA ? Med Sci (Paris) 2009 ; 25 : 855-857